<DOC>
	<DOCNO>NCT02579564</DOCNO>
	<brief_summary>The purpose multi-center clinical trial verify effective local control malignant pleural effusion NSCLC patient thoracic cavity perfusion recombinant human adenovirus type 5 injection recombinant human Endostatin injection ( Endostar ) compare cisplatin perfusion , acceptable side effect .</brief_summary>
	<brief_title>Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 Endostatin Injections Treatment Malignant Hydrothorax NSCLC Patients</brief_title>
	<detailed_description>Malignant pleural effusion , malfunction circulatory respiratory system , common complication advance NSCLC , finally decrease quality life lifespan . Nowadays , still challenge effectively control malignant pleural effusion . In multi-center randomized control clinical trial , 134 NSCLC patient diagnose malignant pleural effusion first time enroll . Based systemic chemotherapy pleural cavity perfusion , eligible patient randomly assign treatment group ( recombinant human adenovirus type 5 Endostatin injection ) control group ( cisplatin ) ratio 1:1 . Local control rate side effect record respectively . The anticipation treatment group obtain faster longer control pleural effusion .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Hydrothorax</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1. age 1875 yr ; 2 . Kamofsky score ( KPS ) â‰¥70 , predict lifespan &gt; 3 month ; 3 . Enough function vital organ , heart , liver kidney ; 4 . Advanced NSCLC diagnose cytology pathology 5 . Unilateral bilateral malignant pleural effusion first time ; 6 . Patients consider malignant pleural effusion cytology biomarkers ( CEA , CA199 , CA125 ) pleural effusion ; 7 . Without systemic infection high fever ; 8 . Without active EGFR mutation unwilling target molecular therapy ; 9 . NO Anti tumor Radiotherapy chemotherapy molecular target therapy , Received Anti tumor Radiotherapy chemotherapy molecular clinical remission three month past month , disease progress pleural cavity effusion n't use systemic local anti tumor treatment . 10 . No pleural cavity injection antineoplastic drug . 1 . Nonmalignant pleural effusion ; 2 . Pleural effusion cause malignant tumor ; 3 . Allergic Recombinant human adenovirus type 5 injection Endostar ; 4 . Pregnant lactation woman ; 5 . Previously use Medicine treat NSCLC pleural cavity effusion Systemic pleural cavity perfusion treatment one month prior enrollment ; 6 . Previously use diuretic , albumin antiangiogenesis drug , dexamethasone one month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>